CAMBRIDGE, Mass., Oct. 22, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, announced today that it will host a live webcast to present and discuss the newly disclosed, late-breaking 48-week Phase 3 clinical data in China for...

People

6 Energy-Saving Tips

COOFANDY Marks 10th Anniversary with Dual Silver Awards at Berlin and...

Ogden Electrician Launches Range of Electrical Services in Ogden, Utah

FND ECOMMERCE: Full-Service UK Amazon Agency Announces Launch of New Website

iHerb Introduces California Gold Nutrition® BEAUTY

Plant Stem Cell Market Review 2020-2024 and Forecast 2025-2030: Unilever, Renature...

U.S. Organic Personal Care Market Report 2025: Millennials and Gen Z...

LGI Homes Expands Presence in Winston-Salem with Five New Communities in...

Lover of Music and Writer Debuts A Poetic Exploration of Life’s...

Hair Transplant Market To Worth Over US$ 41.01 Billion By 2033...

Crystal Bridges Museum Announces Acquisition of Historic Tiffany Studios Stained-Glass Window

Featured

Vor Bio to Host Webcast on Late-Breaking China Phase 3 Telitacicept...

6 Energy-Saving Tips

Saudia Unveils SV Lifestyle Brand at Riyadh Fashion Week

All Star Digital and Dart Co Launch One Hitters: Exclusive Partnership...

Vor Bio to Host Webcast on Late-Breaking China Phase 3 Telitacicept...